JP2018504369A - 放射性医薬品からアセトアルデヒドを除去する方法 - Google Patents
放射性医薬品からアセトアルデヒドを除去する方法 Download PDFInfo
- Publication number
- JP2018504369A JP2018504369A JP2017527839A JP2017527839A JP2018504369A JP 2018504369 A JP2018504369 A JP 2018504369A JP 2017527839 A JP2017527839 A JP 2017527839A JP 2017527839 A JP2017527839 A JP 2017527839A JP 2018504369 A JP2018504369 A JP 2018504369A
- Authority
- JP
- Japan
- Prior art keywords
- acetaldehyde
- radiopharmaceutical
- aldehyde scavenger
- present
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 title claims description 76
- 239000012217 radiopharmaceutical Substances 0.000 title claims description 28
- 229940121896 radiopharmaceutical Drugs 0.000 title claims description 28
- 230000002799 radiopharmaceutical effect Effects 0.000 title claims description 28
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 239000002516 radical scavenger Substances 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 238000002600 positron emission tomography Methods 0.000 claims description 12
- 239000000700 radioactive tracer Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 6
- 150000001299 aldehydes Chemical class 0.000 abstract description 31
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 15
- 238000004817 gas chromatography Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- VXFFXZSNVKXXIB-SCSBXPEDSA-N 2-[(1r,4s,10r,13s,16r,19s,25s)-10-[2-[2-[2-[2-[[2-(2-amino-2-oxoethoxy)acetyl]amino]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]-13-benzyl-25-[3-(diaminomethylideneamino)propyl]-4-[4-[[2-[2-[2-[2-[2-[2-[2-[2-[[2-[(e)-(4-fluorophenyl)methylideneamino]oxyacetyl]ami Chemical compound C([C@@H]1NC(=O)CSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N2)=O)NC1=O)C(=O)NCCOCCOCCOCCNC(=O)COCC(=O)N)CCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CO\N=C\C1=CC=C(F)C=C1 VXFFXZSNVKXXIB-SCSBXPEDSA-N 0.000 description 2
- 108010092045 AH 111585 Proteins 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UOQXIWFBQSVDPP-COJKEBBMSA-N 4-fluoranylbenzaldehyde Chemical compound [18F]C1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-COJKEBBMSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- VVECGOCJFKTUAX-HUYCHCPVSA-N flutemetamol ((18)F) Chemical compound C1=C([18F])C(NC)=CC=C1C1=NC2=CC=C(O)C=C2S1 VVECGOCJFKTUAX-HUYCHCPVSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明では、アルデヒドスカベンジャーは、アミノ−オキシ末端を有する分子であり得る。アミノ−オキシ官能基は極めて反応性であることが知られており、例えば、1ppmの濃度でアセトンを室温においてほぼ完全に変換することができる。
(i)医薬製剤中の遊離アミノオキシ含有賦形剤、
(ii)医薬製剤を通過させる、結合アミノキシ含有官能基を含有する固相材料、
(iii)個々の用量/QC/マイクロ/保持試料バイアルの初回分配の際に使用される分配流体経路の一部としてのカートリッジ/濾過ユニットの一部、
(iv)臨床使用の直前の分配に使用される分配流体経路の一部としてのカートリッジ/濾過ユニットの一部、
(v)放射性トレーサの製造直後に、患者用量投与のためにシリンジを充填するときに医薬製剤を通過させるカートリッジ/濾過ユニットの一部、及び/又は
(vi)臨床使用の直前に、患者用量投与のためにシリンジを充填するときに医薬製剤を通過させるカートリッジ/濾過ユニット
として提供することができる。
本発明では、医薬製剤は最終放射性医薬製剤を指すものとする。一実施形態では、医薬製剤は、哺乳動物投与に適切な形態であり、無菌で、発熱物質非含有の、毒性及び有害事象を起こす化合物を含まない、生体適合性のpH(およそpH4.0から10.5)において製剤化された製剤を意味する。このような製剤は、インビボで塞栓を引き起こし得るリスクのある微粒子を含まず、生物学的流体(例えば血液)との接触において沈降を起こさないように製剤化される。このような製剤はさらに、生物学的に適合性の賦形剤、好ましくは等張性の賦形剤だけを含有する。本発明では、医薬製剤は放射性医薬品及び溶媒を含み、各々は本明細書に記載されている。医薬製剤は、限定するものではないが、自動合成機(例えば、FASTlab(登録商標))を含む当分野で公知の任意の手段によって製造することができる。
本発明では、放射性医薬品は、インビトロ又はインビボイメージングに適切な任意の放射標識化合物を含むことができる。本発明の一実施形態では、放射標識化合物は、インビボイメージングに適切である。インビボイメージングに適切であるために、放射性医薬品は哺乳動物投与に適した形態で適切に提供され、哺乳動物対象単独をイメージングすることによって得られる画像よりも、目的の領域又は器官においてより鮮明な画像の提供を支援する。好ましい実施形態では、放射性医薬品は、陽電子放射断層撮影(PET)トレーサである。好ましい実施形態では、放射性医薬品は、18F PETトレーサである。適切な18F PETトレーサの非限定的な例としては、以下の[18F]フルシクラチド、[18F]フルテメタモール、及び[18F]GE180が挙げられるが、これらに限定されない。
本発明では、溶媒は、医薬製剤における使用に適切な、当分野において公知の任意の有機溶媒を含んでよい。好ましい実施形態では、溶媒はアルコールを含む。好ましい実施形態では、溶媒はエタノール、イソプロパノール又はバイオアルコールである。好ましい実施形態では、溶媒はエタノールである。
HPLCを使用してフルシクラチド(18F)注射液試料中のアセトアルデヒド含有量を分析する実験において、アセトアルデヒドを、AH111695を用いてUV吸収性フルシクラチド類似体AH111930に誘導化した(スキーム1)。
Claims (19)
- アルデヒドスカベンジャーを医薬製剤と組合せるステップを含む、医薬製剤中のアセトアルデヒドの形成を定量、除去又は制御するための方法。
- アルデヒドスカベンジャーがアミノ−オキシ末端を有する分子である、請求項1に記載の方法。
- アルデヒドスカベンジャーが以下の構造を有する、請求項1に記載の方法。
- 医薬製剤が放射性医薬品及び溶媒を含む、請求項1乃至請求項3のいずれか1項に記載の方法。
- 放射性医薬品が陽電子放射断層撮影(PET)トレーサである、請求項4に記載の方法。
- 放射性医薬品が18F PETトレーサである、請求項5に記載の方法。
- 放射性医薬品が以下の化合物の群から選択される、請求項6に記載の方法。
- 溶媒がアルコールを含む、請求項4乃至請求項7のいずれか1項に記載の方法。
- アルコールが、エタノール、イソプロパノール及びバイオアルコールからなる群から選択される、請求項8に記載の方法。
- アルコールがエタノールである、請求項9に記載の方法。
- アルデヒドスカベンジャーと放射性医薬品と溶媒とを含む組成物。
- アルデヒドスカベンジャーがアミノ−オキシ末端を有する分子である、請求項11に記載の組成物。
- アルデヒドスカベンジャーが以下の構造を有する、請求項11に記載の組成物。
- 放射性医薬品が陽電子放射断層撮影(PET)トレーサである、請求項11乃至請求項13のいずれか1項に記載の組成物。
- 放射性医薬品が18F PETトレーサである、請求項11乃至請求項14のいずれか1項に記載の組成物。
- 放射性医薬品が以下の化合物の群から選択される、請求項15に記載の組成物。
- 溶媒がアルコールを含む、請求項11乃至請求項16のいずれか1項に記載の組成物。
- アルコールがエタノール、イソプロパノール又はバイオアルコールである、請求項17に記載の組成物。
- アルコールがエタノールである、請求項18に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462087371P | 2014-12-04 | 2014-12-04 | |
US62/087,371 | 2014-12-04 | ||
PCT/EP2015/078682 WO2016087653A1 (en) | 2014-12-04 | 2015-12-04 | Method of removing acetaldehyde from radioactive pharmaceuticals |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020196848A Division JP7164583B2 (ja) | 2014-12-04 | 2020-11-27 | 放射性医薬品からアセトアルデヒドを除去する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018504369A true JP2018504369A (ja) | 2018-02-15 |
JP6842415B2 JP6842415B2 (ja) | 2021-03-17 |
Family
ID=55025003
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017527839A Active JP6842415B2 (ja) | 2014-12-04 | 2015-12-04 | 放射性医薬品からアセトアルデヒドを除去する方法 |
JP2020196848A Active JP7164583B2 (ja) | 2014-12-04 | 2020-11-27 | 放射性医薬品からアセトアルデヒドを除去する方法 |
JP2022168399A Active JP7379638B2 (ja) | 2014-12-04 | 2022-10-20 | 放射性医薬品からアセトアルデヒドを除去する方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020196848A Active JP7164583B2 (ja) | 2014-12-04 | 2020-11-27 | 放射性医薬品からアセトアルデヒドを除去する方法 |
JP2022168399A Active JP7379638B2 (ja) | 2014-12-04 | 2022-10-20 | 放射性医薬品からアセトアルデヒドを除去する方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US10660966B2 (ja) |
EP (1) | EP3226884B1 (ja) |
JP (3) | JP6842415B2 (ja) |
KR (1) | KR102458116B1 (ja) |
CN (1) | CN106999603B (ja) |
AU (1) | AU2015356971B2 (ja) |
IL (1) | IL252186B (ja) |
RU (1) | RU2719399C2 (ja) |
WO (1) | WO2016087653A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102458116B1 (ko) | 2014-12-04 | 2022-10-24 | 지이 헬쓰케어 리미티드 | 방사성 약제로부터의 아세트알데히드의 제거 방법 |
US11969764B2 (en) | 2016-07-18 | 2024-04-30 | Sortera Technologies, Inc. | Sorting of plastics |
IT202000012334A1 (it) * | 2020-05-26 | 2021-11-26 | Repi S R L | Formulazione liquida comprendente uno scavenger di aldeidi. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06503790A (ja) * | 1990-12-13 | 1994-04-28 | ジェネンテク,インコーポレイテッド | 保存安定性薬物のための容器系 |
JP2004073377A (ja) * | 2002-08-13 | 2004-03-11 | Takeda Chem Ind Ltd | 固形医薬組成物中の有効成分の安定化方法 |
WO2004037293A1 (ja) * | 2002-10-22 | 2004-05-06 | Dainippon Pharmaceutical Co., Ltd. | 安定化組成物 |
JP2008500283A (ja) * | 2004-05-11 | 2008-01-10 | ハマースミス・イメイネット・リミテッド | 精製法 |
JP2014500268A (ja) * | 2010-12-09 | 2014-01-09 | ジーイー・ヘルスケア・リミテッド | 放射性トレーサー組成物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MC2260A1 (fr) | 1990-06-18 | 1993-04-26 | Dow Chemical Co | Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation |
WO2002083210A1 (en) * | 2001-04-13 | 2002-10-24 | Jean-Luc Morelle | Process and device for preparing radiopharmaceutical products for injection |
GB0305704D0 (en) | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
GB0420344D0 (en) | 2004-09-14 | 2004-10-13 | Amersham Plc | Diagnostic compounds |
GB0516564D0 (en) | 2005-08-12 | 2005-09-21 | Ge Healthcare Ltd | Fluorination process |
CA2694084C (en) | 2007-08-30 | 2015-07-07 | Ge Healthcare Limited | Radiopharmaceutical composition |
WO2009035959A2 (en) * | 2007-09-10 | 2009-03-19 | Ge Healthcare Limited | Radiofluorination methods |
AU2008324186B2 (en) * | 2007-11-07 | 2014-02-13 | Ge Healthcare Bv | Stabilization of radiopharmaceuticals |
GB0905328D0 (en) | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
PL2509637T3 (pl) | 2009-10-08 | 2016-12-30 | Sposób oczyszczania | |
ES2688574T3 (es) | 2010-03-26 | 2018-11-05 | Ge Healthcare Limited | Derivados de indol tricíclicos como ligandos de PBR |
GB201021263D0 (en) | 2010-12-15 | 2011-01-26 | Ge Healthcare Ltd | Solid phase extraction method |
GB201202420D0 (en) | 2012-02-13 | 2012-03-28 | Ge Healthcare Ltd | Radiotracer compositions |
AU2013344464A1 (en) * | 2012-11-16 | 2015-05-21 | The Regents Of The University Of California | Pictet-Spengler ligation for protein chemical modification |
KR102458116B1 (ko) | 2014-12-04 | 2022-10-24 | 지이 헬쓰케어 리미티드 | 방사성 약제로부터의 아세트알데히드의 제거 방법 |
-
2015
- 2015-12-04 KR KR1020177014839A patent/KR102458116B1/ko active IP Right Grant
- 2015-12-04 RU RU2017116966A patent/RU2719399C2/ru active
- 2015-12-04 EP EP15816682.7A patent/EP3226884B1/en active Active
- 2015-12-04 AU AU2015356971A patent/AU2015356971B2/en active Active
- 2015-12-04 WO PCT/EP2015/078682 patent/WO2016087653A1/en active Application Filing
- 2015-12-04 JP JP2017527839A patent/JP6842415B2/ja active Active
- 2015-12-04 US US15/532,938 patent/US10660966B2/en active Active
- 2015-12-04 CN CN201580065805.7A patent/CN106999603B/zh active Active
-
2017
- 2017-05-09 IL IL252186A patent/IL252186B/en active IP Right Grant
-
2020
- 2020-04-15 US US16/849,881 patent/US11389538B2/en active Active
- 2020-11-27 JP JP2020196848A patent/JP7164583B2/ja active Active
-
2022
- 2022-06-13 US US17/838,638 patent/US11964020B2/en active Active
- 2022-10-20 JP JP2022168399A patent/JP7379638B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06503790A (ja) * | 1990-12-13 | 1994-04-28 | ジェネンテク,インコーポレイテッド | 保存安定性薬物のための容器系 |
JP2004073377A (ja) * | 2002-08-13 | 2004-03-11 | Takeda Chem Ind Ltd | 固形医薬組成物中の有効成分の安定化方法 |
WO2004037293A1 (ja) * | 2002-10-22 | 2004-05-06 | Dainippon Pharmaceutical Co., Ltd. | 安定化組成物 |
JP2008500283A (ja) * | 2004-05-11 | 2008-01-10 | ハマースミス・イメイネット・リミテッド | 精製法 |
JP2014500268A (ja) * | 2010-12-09 | 2014-01-09 | ジーイー・ヘルスケア・リミテッド | 放射性トレーサー組成物 |
Non-Patent Citations (1)
Title |
---|
"生体試料から糖鎖を自動抽出する装置の実用化に成功", JST(科学技術振興機構)プレスリリース, JPN6019037761, 1 November 2011 (2011-11-01), pages 2 - 10, ISSN: 0004310647 * |
Also Published As
Publication number | Publication date |
---|---|
JP7164583B2 (ja) | 2022-11-01 |
WO2016087653A1 (en) | 2016-06-09 |
KR20220148308A (ko) | 2022-11-04 |
US20220305126A1 (en) | 2022-09-29 |
KR102458116B1 (ko) | 2022-10-24 |
CN106999603A (zh) | 2017-08-01 |
RU2719399C2 (ru) | 2020-04-17 |
US20170360943A1 (en) | 2017-12-21 |
BR112017010484A2 (pt) | 2018-04-03 |
JP2023017790A (ja) | 2023-02-07 |
RU2017116966A (ru) | 2019-01-09 |
EP3226884B1 (en) | 2021-02-17 |
EP3226884A1 (en) | 2017-10-11 |
JP2021063078A (ja) | 2021-04-22 |
KR20170093132A (ko) | 2017-08-14 |
IL252186B (en) | 2020-04-30 |
JP6842415B2 (ja) | 2021-03-17 |
AU2015356971A1 (en) | 2017-06-01 |
CN106999603B (zh) | 2022-05-27 |
JP7379638B2 (ja) | 2023-11-14 |
RU2017116966A3 (ja) | 2019-05-14 |
US10660966B2 (en) | 2020-05-26 |
US20200237921A1 (en) | 2020-07-30 |
AU2015356971B2 (en) | 2021-09-09 |
US11389538B2 (en) | 2022-07-19 |
IL252186A0 (en) | 2017-07-31 |
US11964020B2 (en) | 2024-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7379638B2 (ja) | 放射性医薬品からアセトアルデヒドを除去する方法 | |
JP5717650B2 (ja) | トシラート前駆体からの18f−放射性標識スチリルピリジンおよびその安定性医薬組成物の合成 | |
HUE030172T2 (en) | Tau imaging probe | |
AU2018201405B2 (en) | Radiopharmaceutical synthesis methods | |
Sachin et al. | Synthesis of N 4′-[18F] fluoroalkylated ciprofloxacin as a potential bacterial infection imaging agent for PET study | |
Rahman et al. | Synthesis of ([11C] carbonyl) raclopride and a comparison with ([11C] methyl) raclopride in a monkey PET study | |
Kawamura et al. | Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [18F] PM‐PBB3 for clinical applications | |
BR112016003194B1 (pt) | Método para quantificação de 227ac em composições de 223ra | |
JP6226322B2 (ja) | 放射性医薬組成物の製造方法 | |
Buccino et al. | Fully-automated radiosynthesis of the amyloid tracer [11 C] PiB via direct [11 C] CO 2 fixation-reduction | |
KR102668112B1 (ko) | 방사성 약제로부터의 아세트알데히드의 제거 방법 | |
Huiban et al. | Fully automated synthesis of the M1 receptor agonist [11C] GSK1034702 for clinical use on an Eckert & Ziegler Modular Lab system | |
JP2009539989A (ja) | 注射用アルテスン酸の処方及び製造方法 | |
Liang et al. | Three-dimensional positron emission tomography/computed tomography analysis of 13NO3− uptake and 13N distribution in growing kohlrabi | |
Ikenuma et al. | Synthesis of (R, S)-isoproterenol, an inhibitor of tau aggregation, as an 11C-labeled PET tracer via reductive alkylation of (R, S)-norepinephrine with [2-11C] acetone | |
JP6472493B2 (ja) | 放射性医薬組成物 | |
BR112017010484B1 (pt) | Método para controlar a formação de acetaldeído em uma formulação farmacêutica radioativa | |
Schönbächler et al. | PET imaging of dopamine transporters in the human brain using [11C]-β-CPPIT, a cocaine derivative lacking the 2β-ester function | |
Takatani et al. | Synthesis of L‐[5‐11C] Leucine and L‐α‐[5‐11C] Methylleucine via Pd0‐mediated 11C‐Methylation and Microfluidic Hydrogenation: Potentiality of Leucine PET Probes for Tumor Imaging | |
Neelamegam et al. | A report of the automated radiosynthesis of the tau positron emission tomography radiopharmaceutical,[18F]‐THK‐5351 | |
Carpinelli et al. | Radiosynthesis of [123I] βCIT, a selective ligand for the study of the dopaminergic and serotoninergic systems in human brain | |
Huang et al. | A combined simple bubbling method with high performance liquid chromatography purification strategy with higher radiochemical yield and purity and faster preparation of carbon-11-raclopride | |
Seunig | MASTERARBEIT/MASTER’S THESIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181122 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20190607 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190918 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191008 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191223 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200407 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201127 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201127 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20201208 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201222 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210105 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6842415 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |